Xilingio M 10mg/5mg/1000mg Tablet ER

Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone activity, increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity. The extended-release formulation allows for once-daily dosing, improving patient adherence and minimizing gastrointestinal side effects commonly associated with immediate-release metformin.

Xilingio M should be used alongside diet and exercise to achieve optimal glycemic control. Caution is advised in patients with renal impairment, hepatic dysfunction, or risk factors for lactic acidosis. Regular monitoring of renal function, blood glucose, and potential adverse effects such as urinary tract infections or hypoglycemia is recommended. This combination therapy offers a comprehensive approach to glycemic management by targeting multiple pathophysiological mechanisms of type 2 diabetes.